Erratum: Progressive breathlessness in COPD - The role of hyperinflation and its pharmacological management (Primary Care Respiratory Journal (2005) 14,6 (285.293) DOI:10.1016/j.pcrj.2005.08.005);Progressive breathlessness in COPD - The role of hyperinflation and its pharmacological management

Primary Care Respiratory Journal

Volumn 14, Issue 6, 2005, Pages 285-293

  Price, David ^a   Freeman, Daryl ^a   Kaplan, Alan ^b   Østrem, Anders ^a   Reid, James ^c   Molen, Thys Van Der ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b Family Physician Airways Group of Canada   (Canada)

^c UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIINFLAMMATORY AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; FORMOTEROL; NICOTINE; SALMETEROL; TIOTROPIUM BROMIDE;

ANTIINFLAMMATORY ACTIVITY; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORRELATION ANALYSIS; DISEASE COURSE; DYSPNEA; EARLY DIAGNOSIS; EXERCISE TOLERANCE; FORCED EXPIRATORY VOLUME; HUMAN; INSPIRATORY RESERVE VOLUME; LUNG FUNCTION; LUNG INFLATION; NOSE AIRFLOW; OXYGEN THERAPY; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; QUALITY OF LIFE; REVIEW; SMOKING; SMOKING CESSATION; SYMPTOM; THORAX WALL; TOBACCO DEPENDENCE;

EID: 28444457334     PISSN: 14714418     EISSN: 14751534     Source Type: Journal    
DOI: 10.1016/j.pcrj.2006.02.003     Document Type: Erratum

References (57)

1. World Health Organization. World Health Report 1997: Conquering suffering, enriching humanity. 1997.
2. C.J.L. Murray, and A.D. Lopez Alternative projections of mortality and disability by cause 1990-2020: Global burden of disease study Lancet 349 1997 1498 1504
3. D.A. Mahler, K. Faryniarz, and D. Tomlinson Impact of dyspnea and physiologic function on general health status in patients with chronic obstructive pulmonary disease Chest 102 2 1992 395 401
4. S.D. Sullivan, S.D. Ramsey, and T.A. Lee The economic burden of COPD Chest 117 2000 5S 9S
5. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Update 2004. http://www.goldcopd.com/revised pdf 2004.
6. B.R. Celli, W. MacNee committee members Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper Eur Respir J 23 2004 932 946
7. P.K. Jeffery Comparison of the structural and inflammatory features of COPD and asthma. Giles F Filley lecture Chest 117 5 2000 251S 260S
8. J.E. Anderson, D.E. Jorenby, W.J. Scott, and M.C. Fiore Treating tobacco use and dependence: an evidence-based clinical practice guideline for tobacco cessation Chest 121 3 2002 932 941
9. R. West, A. McNeill, and M. Raw Smoking cessation guidelines for health professionals: an update. Health Education Authority Thorax 55 12 2000 987 999
10. The Tobacco Use, Dependence Clinical Practice Guideline Panel Staff, Consortium Representatives A clinical practice guideline for treating tobacco use and dependence: A US Public Health Service report JAMA 283 24 2000 3244 3254
11. D.E. O'Donnell, M.I.U. Lam, and K.A. Webb Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease Am J Respir Crit Care Med 160 2 1999 542 549
12. D.E. O'Donnell, T. Flüge, and F. Gerken Effects of tiotropium on lung hyperinflation, dyspnea and exercise tolerance in patients with COPD Eur Respir J 23 6 2004 832 840
13. D.E. O'Donnell, N. Voduc, M. Fitzpatrick, and K.A. Webb Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease Eur Respir J 24 1 2004 86 94
14. ACCP/AACVPR Pulmonary Rehabilitation Guidelines Panel. Pulmonary rehabilitation. Joint ACCP/AACVPR evidence-based guidelines. Chest 1997;112(5):1363-96.
15. J.M. Anto, P. Vermeire, J. Vestbo, and J. Sunyer Epidemiology of chronic obstructive pulmonary disease Eur Respir J 17 5 2001 982 994
16. D. Price, and D. Freeman The BREATH (Breathlessness Research, Expectations and Treatment hopes) study: findings of a pilot study in four countries Primary Care Repiratory Journal 11 Supplement 1 2004 s12 s14
17. C.P. van Schayck, J.M.C. Loozen, E. Wagena, R.P. Akkermans, and G.J. Wesseling Detecting patients at a high risk of developing chronic obstructive pulmonary disease in general practice: cross sectional case finding study Brit Med J 324 2002 1370 1374
18. H. Mullerova, J. Wedzicha, J.B. Soriano, and J. Vestbo Validation of a chronic obstructive pulmonary disease screening questionnaire for population surveys Respir Med 98 1 2004 78 83
19. D. Price, R.J. Tinkelman, S. Nordyke, and R.J. Isonaka Utility of a symptom-based questionnaire for identifying COPD in smokers Am J Respir Crit Care Med 169 2004 A605
20. S. Rennard, M. Decramer, and P.M.A. Calverley Impact of COPD in North America and Europe in 2000: subjects' perspective of Confronting COPD International Survey Eur Respir J 20 2002 799 805
21. J.A. Katula, W.J. Rejeski, K.L. Wickley, and M.J. Berry Perceived difficulty, importance, and satisfaction with physical function in COPD patients Health Qual Life Outcomes 2 1 2004 18
22. D.A. Mahler, and P.W. Jones Measurement of dyspnea and quality of life in advanced lung disease Clin Chest Med 18 3 1997 457 469
23. D.E. O'Donnell Breathlessness in patients with chronic airflow limitation. Mechanisms and management Chest 106 1994 904 912
24. D.E. O'Donnell Ventilatory limitations in chronic obstructive pulmonary disease Med Sci Sports Exerc 33 7 Suppl 2001 S647 S655
25. Pride NB, Milic-Emil J. Lung mechanics. 1995;First(7):135-60.
26. D.E. Leith, and R. Brown Human lung volumes and the mechanisms that set them Eur Respir J 13 2 1999 468 472
27. G. Ferguson The ins and outs of breathing: an overview of lung mechanics Eur Respir Rev 13 89 2004 30 34
28. V. Leyenson, S. Furukawa, A. Kuzma, F. Cordova, J. Travaline, and G. Criner Correlation of changes in quality of life after lung volume reduction surgery with changes in lung function, exercise, and gas exchange Chest 118 3 2000 728 735
29. A.M. Ciccone, B.F. Meyers, and T.J. Guthrie Long-term outcome of bilateral lung volume reduction in 250 consecutive patients with emphysema J Thorac Cardiovasc Surg 125 3 2003 513 525
30. E.N. Kosmas, J. Milic-Emili, and A. Polychronaki Exercise-induced flow limitation, dynamic hyperinflation and exercise capacity in patients with bronchial asthma Eur Respir J 24 3 2004 378 384
31. F.C. Sciurba Physiologic similarities and differences between COPD and asthma Chest 126 2 Suppl 2004 117S 124S
32. 1 JAMA 272 19 1994 1497 1505
33. D. Tashkin, R.E. Kanner, and W. Bailey Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial Lancet 357 9268 2001 1571 1575
34. T.L. Feenstra, M.L. Van Genugten, R.T. Hoogenveen, E.F. Wouters, and M.P. Rutten-van Molken The impact of aging and smoking on the future burden of chronic obstructive pulmonary disease: a model analysis in the Netherlands Am J Respir Crit Care Med 164 4 2001 590 596
35. F. Maltais, P. LeBlanc, J. Jobin, and R. Casaburi Peripheral muscle dysfunction in chronic obstructive pulmonary disease Clin Chest Med 21 4 2000 665 677
36. Y. Lacasse, E. Wong, G.H. Guyatt, D. King, D.J. Cook, and R.S. Goldstein Meta-analysis of respiratory rehabilitation in chronic obstructive pulmonary diseases Lancet 348 1996 1115 1119
37. Report of the Medical Research Council Working Party Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema Lancet 1 1981 681 686
38. S.P. Tarpy, and B.R. Celli Long-term oxygen therapy N Engl J Med 333 1995 710 714
39. P. Palange, G. Valli, and P. Onorati Effect of heliox on lung dynamic hyperinflation, dyspnea, and exercise endurance capacity in COPD patients J Appl Physiol 97 5 2004 1637 1642
40. D.A. Strumpf, R.P. Millman, and C.C. Carlisle Nocturnal positive-pressure ventilation via nasal mask in patients with severe chronic obstructive pulmonary disease Am Rev Respir Dis 144 6 1991 1234 1239
41. P.J. Barnes Mechanisms in COPD. Differences from asthma Chest 117 2 2000 10S 14S
42. P.J. Barnes, K. Ito, and I.M. Adcock Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase Lancet 363 9410 2004 731 733
43. Global Initiative for Asthma. NHLBI/WHO Workshop Report: Global Strategy for Asthma Management and Prevention - Updated April 2002. 2002; Volume NIH Publication No 02-3659.
44. N.J. Gross, E. Co, and M.S. Skorodin Cholinergic bronchomotor tone in COPD. Estimates of its amount in comparison with that in normal subjects Chest 96 5 1989 984 987
45. Barnes PJ. Managing chronic obstructive pulmonary disease. London: Science Press Ltd., 1999.
46. COMBIVENT Inhalation Aerosol Study Group In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial Chest 105 5 1994 1411 1419
47. J.P. Karpel, A. Kotch, M. Zinny, J. Pesin, and W. Alleyne A comparison of inhaled ipratropium, oral theophylline plus inhaled β-agonist, and the combination of all three in patients with COPD Chest 105 4 1994 1089 1094
48. J.A. van Noord, D.R. de Munck, T.A. Bantje, W.C. Hop, M.L. Akveld, and A.M. Bommer Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium Eur Respir J 15 5 2000 878 885
49. R.L. ZuWallack, D.A. Mahler, and D. Reilly Salmeterol plus theophylline combination therapy in the treatment of COPD Chest 119 6 2001 1661 1670
50. M. Cazzola, F.D. Marco, and P. Santus The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD Pulm Pharmacol Ther 17 1 2004 35 39
51. Casaburi R, Kakafka D, Cooper C, Witek J, Kesten S. Improvement in endurance time with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 2004; Volume in press.
52. M.F. Newton, D.E. O'Donnell, and L. Forkert Response of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflation Chest 121 4 2002 1042 1050
53. R. Duranti, M. Filippelli, and R. Bianchi Inspiratory capacity and decrease in lung hyperinflation with albuterol in COPD Chest 122 6 2002 2009 2014
54. F. Di Marco, J. Milic-Emili, and B. Boveri Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD Eur Respir J 21 1 2003 86 94
55. B. Celli, R. ZuWallack, S. Wang, and S. Kesten Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes Chest 124 5 2003 1743 1748
56. D. Tashkin, and S. Kesten Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses Chest 123 (5 2003 1441 1449
57. J.J. Liesker, V. Van De Velde, and M. Meysman Effects of formoterol (Oxis Turbuhaler) and ipratropium on exercise capacity in patients with COPD Respir Med 96 8 2002 559 566